Advertisement

Archives of Sexual Behavior

, Volume 48, Issue 3, pp 923–933 | Cite as

A Real-World Study on Antidepressant-Associated Sexual Dysfunction in 2144 Outpatients: The SALSEX I Study

  • Angel L. MontejoEmail author
  • Julia Calama
  • Fernando Rico-Villademoros
  • Laura Montejo
  • Nerea González-García
  • Jesús Pérez
  • SALSEX Working Study Group
Original Paper

Abstract

The objective of this cross-sectional study was to evaluate the frequency, impact, and management of sexual dysfunction associated with commonly prescribed antidepressants available in psychiatry outpatient clinics in Spain. We recruited 2163 adult patients who had undergone treatment with antidepressants for at least 8 weeks and had a history of normal sexual functioning before the prescription of the antidepressant, except for mildly impaired libido. We used the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) for evaluating the frequency and tolerance of sexual dysfunction and whether this side effect was spontaneously reported. Overall, 79% patients showed sexual dysfunction, as indicated by a total score ≥ 3 on the PRSexDQ-SALSEX; 64% showed moderate–severe sexual dysfunction, with no differences between men and women on these outcomes. In the multivariate logistic regression analysis, treatment with a serotonergic antidepressant and having a severe clinical state of psychiatric illness were the factors associated with the highest likelihood of presenting with sexual dysfunction. Sexual dysfunction was spontaneously reported by 838 (41%) of the 2066 evaluable patients for this outcome. Among patients with sexual dysfunction, this condition was poorly tolerated by 22% of the patients, with these frequencies being significantly higher in men than in women. The most frequently used strategies employed by the psychiatrists in our study for dealing with sexual dysfunction were switching to another antidepressant (34%) and waiting for spontaneous resolution (33%). In conclusion, our results indicate that despite being a well-known, long-standing side effect of antidepressants, sexual dysfunction continues to be extremely common in patients receiving antidepressants, especially serotonergic ones, potentially jeopardizing treatment success in a substantial proportion of patients. There are important sex differences in the reporting and tolerance of sexual dysfunction that require further investigation.

Keywords

Sexual functioning Sexual dysfunction Antidepressant Psychotropic Sex differences 

Notes

Acknowledgements

The SALSEX Working Study Group: José Antonio Aguado Mañas (Valladolid, Spain); José Antonio Agüero (Tudela, Spain); Maite Aldabatreku (Azpeitia, Spain); Ángeles Alonso de La Torre (León, Spain); Paloma Alonso Quintanilla (Valladolid, Spain); Pablo Álvarez Lobato (Valladolid, Spain); María Teresa Amboage Paz (A Coruña, Spain); José Antonio Antón (Logroño, Spain); Jesús Armendia González (San Sebastián, Spain); Jesús Artal Simón (Santander, Spain); Aitxiber Artetxe Chomón (Algorta, Spain); Concepción Babás Rodríguez (Carballo, Spain); Lorena Bartolomé Herrero (Zamora, Spain); Eva Bobadilla Pérez (A Coruña, Spain); Berta Bote Bonaechea (Salamanca, Spain); Julio Brenlla González (Santiago de Compostela, Spain); Javier Caballer García (Oviedo, Spain); Pilar Calvo (Tudela, Navarra, Spain); Marisol Campos (Espartero, Spain); Carlos Castro Dono (Betanzos, Spain); José Manuel Cornés Iglesias (Santiago de Compostela, Spain); Juan Carlos Díaz Del Valle (A Coruña, Spain); Francisco Doce Feliz (A Coruña, Spain); Amaia Echevarria Alfonso (Eibar, Spain); José Ramón Eizmendi Izquierdo (Algorta, Spain); José Antonio Espina Barrio (Valladolid, Spain); Manuel Espiñeira Álvarez (A Coruña, Spain); Carlos Fernández Atienzar (Valladolid, Spain); José Manuel Fernández Cuesta (Santander, Spain); Óscar Fernández Torre (Arriondas, Spain); Eva Fontenla Vivanco (A Coruña, Spain); Isabel Freire (Tudela, Spain); María Teresa Gallego De Dios (Salamanca, Spain); María Carmen García Mahia (A Coruña, Spain); Juan Antonio García Mellado (Zamora, Spain); María García Nicolás (Calahorra, Spain); Fidel García Sánchez (Valladolid, Spain); Llanyra García Ullán (Salamanca, Spain); Esther García Usieto (Torrelavega, Spain); Felisa Gómez Robina (Ávila, Spain); Sonia González Bardanca (A Coruña, Spain); Vanessa González De María (Segovia, Spain); Pilar González Izquierdo (Langreo, Spain); Esperanza González Marín (Salamanca, Spain); Rosa González Martínez (Carballo, Spain); Emilio González Pablos (Palencia, Spain); Ana Isabel González Vázquez (A Coruña, Spain); Luis Gutiérrez-Moyano Zinnmerman (Ourense, Spain); Miguel Ángel Hernández de Las Heras (Soria, Spain); Mario Javier Hernández González (Mieres, Spain); Marcos Huerta González (Gijón, Spain); Fernanda Iglesias Abella (Ourense, Spain); Guillermo Iglesias Lorenzo (Ferrol, Spain); Ignacio Iraizoz (Pamplona, Spain); Juan Larumbe Ochoa (Vitoria, Spain); José María Lomba Borrajo (Ourense, Spain); José López Ilundain (Burlada, Spain); Mario Martínez Pérez (Ponferrada, Spain); Jacqueline Mayoral Van Son (Santander, Spain); María Ángeles Medina (Burgos, Spain); Carmen Medina Merino (León, Spain); Begoña Mendíbil Eguiluz (Algorta, Spain); María Jesús Merino García (Gijón, Spain); Begoña Michel Zugazabeitia (San Sebastián, Spain); Ana Monedero Justel (Eibar, Spain); Blanca Morera (San Sebastián, Spain); Inés Munarriz (Pamplona, Spain); Julio Muñoz García (Santander, Spain); Sergio Ocio León (Mieres, Spain); Magdalena Otaño (Tudela, Spain); Luis Pacheco Yañez (Bilbao, Spain); Mónica Pastor (Logroño, Spain); José María Pelayo Terán (Arriondas, Spain); Mercedes Pérez López (Zamora, Spain); Fernando Pérez Nievas (Burlada, Spain); José Alfredo Pérez Portilla (Lugo, Spain); Nieves Prieto Mestre (Salamanca, Spain); Pablo Quiroga Yañez (Ourense, Spain); Francisco Rodríguez Fernández (León, Spain); Víctor Rodríguez Pérez (Castro De Rei, Spain); Milagros Sánchez García (Ávila, Spain); Santiago Sánchez Iglesias (Salamanca, Spain); Ana de Santiago Iaz (Santander, Spain); José de Santiago Sastre (León, Spain); César Sanz de La Garza (Gijón, Spain); Olga Sanz Granado (Burgos, Spain); José Miguel Segovia López (Ponferrada, Spain); Deidre Sierra Biddle (Santander, Spain); Juan Solana Arribas (Laredo, Spain); Antonio Soto Loza (Valladolid, Spain); Luis Suárez Ablanedo (Avilés, Spain); Antonio Terán Prieto (Palencia, Spain); Pedro Trabajo Vega (Arriondas, Spain); Carlos Vázquez Ventoso (A Coruña, Spain); José Luis Villanueva Boyero (Salamanca, Spain); Yolanda Zapico Merayo (Ponferrada, Spain).

Funding

This study was supported by a grant from Fondo de Investigaciones Sanitaria, Instituto de Salud Carlos III, Madrid, Spain (Project Number PS09/02545).

Compliance with Ethical Standards

Conflict of interest

A-LM has been a consultant for, received grant/research support and honoraria from and been on the speakers/advisory board of Eli Lilly, Forum Pharmaceuticals, Rovi, Servier, Shyre, Lundbeck, Otsuka, Janssen, Pfizer and Roche. FR-V has received honoraria for consultancy, providing educational sessions and/or providing medical writing services for Almirall, AstraZeneca, Eli Lilly, Janssen, Lundbeck, Otsuka and Pfizer. The remaining authors declare no conflict of interest related to this manuscript.

Ethical Approval

The study was approved by the Research Ethics Committee of the University Hospital of Salamanca (Spain) and conducted following the principles of the Helsinki declaration.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. Bala, A., Nguyen, H. M. T., & Hellstrom, W. J. G. (2017). Post-SSRI sexual dysfunction: A literature review. Sexual Medicine Reviews, 6, 29–34.CrossRefGoogle Scholar
  2. Baldwin, D. S., Manson, C., & Nowak, M. (2015). Impact of antidepressant drugs on sexual function and satisfaction. CNS Drugs, 29, 905–913.CrossRefGoogle Scholar
  3. Basson, R., Rees, P., Wang, R., Montejo, A. L., & Incrocci, L. (2010). Sexual function in chronic illness. Journal of Sexual Medicine, 7, 374–388.CrossRefGoogle Scholar
  4. Basson, R., & Schultz, W. W. (2007). Sexual sequelae of general medical disorders. The Lancet, 369, 409–424.CrossRefGoogle Scholar
  5. Bonierbale, M., Lancon, C., & Tignol, J. (2003). The ELIXIR study: Evaluation of sexual dysfunction in 4557 depressed patients in France. Current Medical Research and Opinion, 19, 114–124.CrossRefGoogle Scholar
  6. Chen, K. C., Yang, Y. K., Lee, I. H., Yeh, T. L., Lu, R. B., & Chen, P. S. (2008). Sexual dysfunction and physicians’ perception in medicated patients with major depression in Taiwan. Depression and Anxiety, 25, E56–E62.CrossRefGoogle Scholar
  7. Clayton, A. H., Alkis, A. R., Parikh, N. B., & Votta, J. G. (2016). Sexual dysfunction due to psychotropic medications. Psychiatric Clinics of North America, 39, 427–463.CrossRefGoogle Scholar
  8. Clayton, A. H., Croft, H. A., & Handiwala, L. (2014a). Antidepressants and sexual dysfunction: Mechanisms and clinical implications. Postgraduate Medicine, 126, 91–99.CrossRefGoogle Scholar
  9. Clayton, A. H., El Haddad, S., Iluonakhamhe, J. P., Martinez, C. P., & Schuck, A. E. (2014b). Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opinion on Drug Safety, 13, 1361–1374.CrossRefGoogle Scholar
  10. Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., … Metz, A. (2002). Prevalence of sexual dysfunction among newer antidepressants. Journal of Clinical Psychiatry, 63, 357–366.CrossRefGoogle Scholar
  11. Dueñas, H., Brnabic, A. J. M., Lee, A., Montejo, A. L., Prakash, S., Casimiro-Querubin, M. A. L. S., … Raskin, J. (2011a). Treatment-emergent sexual dysfunction with SSRIs and duloxetine: Effectiveness and functional outcomes over a 6-month observational period. International Journal of Psychiatry in Clinical Practice, 15, 242–254.CrossRefGoogle Scholar
  12. Dueñas, H., Lee, A., Brnabic, A. J. M., Chung, K. F., Lai, C. H., Badr, M. G., … Dossenbach, M. (2011b). Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study. International Journal of Psychiatry in Clinical Practice, 15, 80–90.CrossRefGoogle Scholar
  13. Higgins, A., Barker, P., & Begley, C. M. (2006). Iatrogenic sexual dysfunction and the protective withholding of information: In whose best interest? Journal of Psychiatric and Mental Health Nursing, 13, 437–446.CrossRefGoogle Scholar
  14. Keks, N. A., Hope, J., & Culhane, C. (2014). Management of antidepressant-induced sexual dysfunction. Australas Psychiatry, 22, 525–528.CrossRefGoogle Scholar
  15. Kennedy, S. H., Rizvi, S., Fulton, K., & Rasmussen, J. (2008). A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Journal of Clinical Psychopharmacology, 28, 329–333.CrossRefGoogle Scholar
  16. Laumann, E. O., Nicolosi, A., Glasser, D. B., Paik, A., Gingell, C., Moreira, E., & Wang, T. (2005). Sexual problems among women and men aged 40–80 y: Prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. International Journal of Impotence Research, 17, 39–57.CrossRefGoogle Scholar
  17. Laumann, E. O., Paik, A., & Rosen, R. C. (1999). Sexual dysfunction in the United States: Prevalence and predictors. Journal of the American Medical Association, 281, 537–544.CrossRefGoogle Scholar
  18. Lee, K. U., Lee, Y. M., Nam, J. M., Lee, H. K., Kweon, Y. S., Lee, C. T., & Jun, T. Y. (2010). Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting. Psychiatry Investigation, 7, 55–59.CrossRefGoogle Scholar
  19. Lindau, S. T., & Gavrilova, N. (2010). Sex, health, and years of sexually active life gained due to good health: Evidence from two US population based cross sectional surveys of ageing. BMJ, 340, c810.CrossRefGoogle Scholar
  20. Montejo, A. L., Deakin, J. F. W., Gaillard, R., Harmer, C., Meyniel, F., Jabourian, A., … Goodwin, G. (2015a). Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale. Journal of Psychopharmacology, 29, 1119–1128.CrossRefGoogle Scholar
  21. Montejo, A. L., Garcia, M., Espada, M., Rico-Villademoros, F., Llorca, G., & Izquierdo, J. A., for the Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. (2000). Psychometric characteristics of the Psychotropic-Related Sexual Dysfunction questionnaire. Actas Españolas De Psiquiatría, 28, 141–150.Google Scholar
  22. Montejo, A. L., Llorca, G., Izquierdo, J. A., & Rico-Villademoros, F., for the Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. (2001). Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Journal of Clinical Psychiatry, 62(Suppl. 3), 10–21.Google Scholar
  23. Montejo, A., Majadas, S., Rizvi, S. J., & Kennedy, S. H. (2011). The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Human Psychopharmacology: Clinical and Experimental, 26, 537–542.CrossRefGoogle Scholar
  24. Montejo, A. L., Montejo, L., & Baldwin, D. S. (2018). The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry, 17, 3–11.CrossRefGoogle Scholar
  25. Montejo, A. L., Montejo, L., & Navarro-Cremades, F. (2015b). Sexual side-effects of antidepressant and antipsychotic drugs. Current Opinion in Psychiatry, 28, 418–423.CrossRefGoogle Scholar
  26. Montejo, A. L., Prieto, N., Terleira, A., Matias, J., Alonso, S., Paniagua, G., & Portolés, A. (2010). Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. Journal of Psychopharmacology, 24, 111–120.CrossRefGoogle Scholar
  27. Montejo, Á. L., & Rico-Villademoros, F. (2008). Psychometric properties of the Psychotropic-Related Sexual Dysfunction questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. Journal of Sex and Marital Therapy, 34, 227–239.CrossRefGoogle Scholar
  28. Nicolosi, A., Laumann, E. O., Glasser, D. B., Moreira, E. D., Paik, A., & Gingell, C. (2004). Sexual behavior and sexual dysfunctions after age 40: The Global Study of Sexual Attitudes and Behaviors. Urology, 64, 991–997.CrossRefGoogle Scholar
  29. O’Mullan, C., Doherty, M., Coates, R., & Tilley, P. J. M. (2015). Searching for answers and validation: Australian women’s experiences of coping with the adverse sexual effects of antidepressants. Australian Journal of Primary Health, 21, 305–309.CrossRefGoogle Scholar
  30. Phillips, L. (2009). The needs of staff who work with women in single-sex wards. Mental Health Practice, 12, 21–25.CrossRefGoogle Scholar
  31. Quinn, C., Happell, B., & Browne, G. (2011a). Sexuality and consumers of mental health services: The impact of gender and boundary issues. Issues in Mental Health Nursing, 32, 170–176.CrossRefGoogle Scholar
  32. Quinn, C., Happell, B., & Browne, G. (2011b). Talking or avoiding? Mental health nurses’ views about discussing sexual health with consumers. International Journal of Mental Health Nursing, 20, 21–28.CrossRefGoogle Scholar
  33. Reichenpfader, U., Gartlehner, G., Morgan, L. C., Greenblatt, A., Nussbaumer, B., Hansen, R. A., … Gaynes, B. N. (2014). Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: Results from a systematic review with network meta-analysis. Drug Safety, 37, 19–31.CrossRefGoogle Scholar
  34. Serretti, A., & Chiesa, A. (2009). Treatment-emergent sexual dysfunction related to antidepressants. Journal of Clinical Psychopharmacology, 29, 259–266.CrossRefGoogle Scholar
  35. Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews.  https://doi.org/10.1002/14651858.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Williams, V. S. L., Baldwin, D. S., Hogue, S. L., Fehnel, S. E., Hollis, K. A., & Edin, H. M. (2006). Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries. Journal of Clinical Psychiatry, 67, 204–210.CrossRefGoogle Scholar
  37. Williams, V. S. L., Edin, H. M., Hogue, S. L., Fehnel, S. E., & Baldwin, D. S. (2010). Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: Replication in a cross-sectional patient survey. Journal of Psychopharmacology, 24, 489–496.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Neurosciences Area, Instituto de Investigación Biomédica de SalamancaUniversity of SalamancaSalamancaSpain
  2. 2.Psychiatry DepartmentUniversity Hospital of SalamancaSalamancaSpain
  3. 3.Neurosciences InstituteUniversity of GranadaGranadaSpain
  4. 4.Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i SunyerUniversity of Barcelona, Centro de Investigación Biomédica en Red de Salud MentalBarcelonaSpain
  5. 5.Department of Statistics, School of MedicineUniversity of SalamancaSalamancaSpain
  6. 6.Department of PsychiatryUniversity of CambridgeCambridgeUK

Personalised recommendations